CN101010103A - 在20位与整联蛋白拮抗剂缀合的喜树碱衍生物 - Google Patents

在20位与整联蛋白拮抗剂缀合的喜树碱衍生物 Download PDF

Info

Publication number
CN101010103A
CN101010103A CNA2005800152323A CN200580015232A CN101010103A CN 101010103 A CN101010103 A CN 101010103A CN A2005800152323 A CNA2005800152323 A CN A2005800152323A CN 200580015232 A CN200580015232 A CN 200580015232A CN 101010103 A CN101010103 A CN 101010103A
Authority
CN
China
Prior art keywords
group
alkyl
branched
cancer
straight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005800152323A
Other languages
English (en)
Chinese (zh)
Inventor
A·达尔波佐
S·潘克
L·莫里尼
G·加尼尼
M·O·廷蒂
C·皮萨诺
F·祖尼诺
D·阿洛阿蒂
L·维西
S·德拉瓦勒
倪明红
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Istituto Nazionale per lo Studio e la Cura die Tumori
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Istituto Nazionale per lo Studio e la Cura die Tumori
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Istituto Nazionale per lo Studio e la Cura die Tumori, Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Istituto Nazionale per lo Studio e la Cura die Tumori
Publication of CN101010103A publication Critical patent/CN101010103A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CNA2005800152323A 2004-05-13 2005-05-04 在20位与整联蛋白拮抗剂缀合的喜树碱衍生物 Pending CN101010103A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITRM2004A000241 2004-05-13
IT000241A ITRM20040241A1 (it) 2004-05-13 2004-05-13 Camptotecine coniugate in posizione 20 con antagonisti delle integrine.

Publications (1)

Publication Number Publication Date
CN101010103A true CN101010103A (zh) 2007-08-01

Family

ID=35124307

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2005800152323A Pending CN101010103A (zh) 2004-05-13 2005-05-04 在20位与整联蛋白拮抗剂缀合的喜树碱衍生物

Country Status (12)

Country Link
US (1) US20070232639A1 (https=)
EP (1) EP1747019A2 (https=)
JP (1) JP2007537244A (https=)
CN (1) CN101010103A (https=)
AR (1) AR049275A1 (https=)
AU (1) AU2005243834A1 (https=)
BR (1) BRPI0511037A (https=)
CA (1) CA2562572A1 (https=)
IT (1) ITRM20040241A1 (https=)
MX (1) MXPA06012886A (https=)
TW (1) TW200538125A (https=)
WO (1) WO2005110487A2 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104144706A (zh) * 2012-01-27 2014-11-12 弗·哈夫曼-拉罗切有限公司 靶向递送至表达α-V-β-3的细胞的整联蛋白拮抗剂结合物
CN111068068A (zh) * 2019-12-04 2020-04-28 云南民族大学 一种rgd多肽-喜树碱多肽药物偶联物及其应用

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2604284A1 (en) 2007-02-16 2013-06-19 KTB Tumorforschungsgesellschaft mbH Receptor And Antigen Targeted Prodrug
CN105399757A (zh) * 2015-12-29 2016-03-16 遵义医学院 酸敏感型喜树碱-20位去甲斑蝥酸酯衍生物及其抗肿瘤应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19815812A1 (de) * 1998-04-08 1999-10-14 Bayer Ag Modifizierte Cytostatika
ATE216998T1 (de) * 1999-03-09 2002-05-15 Sigma Tau Ind Farmaceuti Camptothecin-derivate mit antitumor-wirkung
US6207832B1 (en) * 1999-04-09 2001-03-27 University Of Pittsburgh Camptothecin analogs and methods of preparation thereof
DE60042700D1 (de) * 1999-09-08 2009-09-17 Markus Albers Integrin-vermittelte arzneimittel-zielrichtung

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104144706A (zh) * 2012-01-27 2014-11-12 弗·哈夫曼-拉罗切有限公司 靶向递送至表达α-V-β-3的细胞的整联蛋白拮抗剂结合物
CN104144706B (zh) * 2012-01-27 2017-03-29 弗·哈夫曼-拉罗切有限公司 靶向递送至表达α‑V‑β‑3的细胞的整联蛋白拮抗剂结合物
CN111068068A (zh) * 2019-12-04 2020-04-28 云南民族大学 一种rgd多肽-喜树碱多肽药物偶联物及其应用

Also Published As

Publication number Publication date
BRPI0511037A (pt) 2007-11-27
EP1747019A2 (en) 2007-01-31
ITRM20040241A1 (it) 2004-08-13
AU2005243834A1 (en) 2005-11-24
MXPA06012886A (es) 2007-02-15
WO2005110487A3 (en) 2007-02-15
TW200538125A (en) 2005-12-01
US20070232639A1 (en) 2007-10-04
JP2007537244A (ja) 2007-12-20
CA2562572A1 (en) 2005-11-24
WO2005110487A2 (en) 2005-11-24
AR049275A1 (es) 2006-07-12

Similar Documents

Publication Publication Date Title
JP2011523415A (ja) 新規な二重標的化抗腫瘍複合体
JP4805917B2 (ja) 細胞分裂阻害剤として７位にて環状ペプチドと接合したカンプトテシン
US20020173468A1 (en) Modified cytostatic agents
CN101010103A (zh) 在20位与整联蛋白拮抗剂缀合的喜树碱衍生物
CA3193485A1 (en) Peptidic conjugates of sn38 useful in the treatment of cancer
KR20010014267A (ko) 맥관형성에 작용하는 시클릭 아자펩티드
US7589099B2 (en) 7-t-butoxyiminomethylcamptothecin conjugated in position 20 with integrin antagonists
HK1107005A (en) Camptothecin derivatives conjugated in position 20 with integrin antagonists
KR20070022292A (ko) 인테그린 길항물질과 20 번 위치에서 공액된 캄토테신유도체
HK1104047A (en) Camptothecins conjugated in position 7 to cyclic peptides as cytostatic agents
KR20070022290A (ko) 인테그린 길항물질과 20 번 위치에서 공액된7-티-부톡시이미노메틸캄토테신
HK1104045A (en) Cyclopeptide derivatives with anti-integrin activity

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1107005

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20070801

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1107005

Country of ref document: HK